Nephropathy - DiabetesontheNet

The jury is out: Encouraging results for paricalcitol, but at what cost?

Low cumulative incidence of ESRD due to nephropathy among people with type 1 diabetes in Sweden

Hyperkalaemia as a result of angiotensin-converting enzyme-inhibitor treatment

Blocking the RAAS: Some answers but more questions

Establishing proteinuria thresholds for clinical practice

RAS blockade for primary prevention of nephropathy in type 1 diabetes

Lowering blood pressure targets

Linking cardiovascular disease and nephropathy in type 1 diabetes

Risk scores for predicting progression in CKD

Strategies for blocking the renin–angiotensin–aldosterone system in diabetic nephropathy: What works?

Better control of microalbuminuria needed in young patients

Pressures are changing for people with nephropathy

Dialysis and diabetes

Beyond blood pressure and glucose control